with Block and Easton that more work is needed if we are to understand how GPs use clinical examination in practice, and how it can be used even better.

Sarah Smithson,
Clinical Lecturer in Medical Education, Keele Medical School.
E-mail: s.e.smithson@keele.ac.uk

Maggie Bartlett,
Senior Lecturer in Medical Education, Keele Medical School.

David Blanchard,
Clinical Lecturer in Medical Education, Keele Medical School.

Matthew Webb,
Clinical Lecturer in Medical Education, Keele Medical School.

REFERENCES

Explaining the role of pharmacists in multidisciplinary care

I would like to address the author’s concern about multidisciplinary care. As stated, his article is not meant to be disparaging towards pharmacists. However, the message delivered is potentially misleading, as it suggests delegating jobs to other professionals could cause patients harm. I would like to clarify the role of pharmacists because it is often misunderstood.

Community pharmacists are here to make an initial assessment and care plan rather than an official diagnosis. If patients return with unresolved symptoms, pharmacists would suggest that the patients see their doctors. Once doctors establish the diagnosis and management plan, pharmacists monitor patients’ therapies in the community, and report drug therapy problems to doctors. It appears that the author is not satisfied with pharmacists’ diagnosis of dark stool. However, making a diagnosis of gastric ulcer probably requires full abdominal examination, digital rectal examination, and endoscopy, which are beyond the scope of practice of many pharmacists.

Anybody is prone to make the wrong initial assessment, because making the right diagnosis requires a lot of clinical experience that aids pattern recognition. Making the right diagnosis also depends on the amount of time spent with patients and choice of investigations ordered. One of pharmacists’ roles is to identify symptoms possibly
caused by drugs, and aid doctors’ differential diagnoses. Pharmacists tend to be excited whenever they identify possible drug therapy problems, because this is their opportunity to shine. However, their enthusiasm can result in criticism and denial by others, as evidenced in a recent study.3

If doctors are concerned about pharmacists’ assessments, doctors can offer interprofessional teaching. Alternatively, doctors can request to see every patient with dark stools who concurrently take iron tablets, but I doubt whether our busy general practice and A&E colleagues would appreciate this approach. Similarly, I myself am grateful to other professionals helping with venipuncture and intravenous cannulation on the wards, and escalating when needed.

To conclude, I acknowledge the author’s concern about potential patient harm, but only if pharmacists are expected to fulfil the entire role of doctors. It would be equally unsafe to expect doctors to perform all of pharmacists’ duties.

Eugene YH Yeung, 
Doctor, Royal Lancaster Infirmary, 
Lancaster. 
E-mail: eugeneyh@gmail.com

Competing interests
Eugene YH Yeung has received salaries from working as a medical doctor and a pharmacist, but neither has paid him to write this letter.

REFERENCES

DOI: https://doi.org/10.3399/bjgp17X692753

Patient use of blood pressure self-screening in general practice waiting rooms: authors’ response

We thank Prof. Smith for his comments.1 We are unaware of any published literature regarding the use of self-screened blood pressure measurements in repeat prescription requests for combined oral contraceptive pill (COCP), although we are currently undertaking some further research exploring the demographics of service users that would show if women of reproductive age are using blood pressure self-screening.

Self-screening systems are available that link a blood pressure monitor and weighing scales to a touch screen that can administer simple questionnaires such as smoking status and potentially ask about COCP side effects and use. These systems integrate the data into the patient’s electronic medical record and alert practice staff to any readings or responses that require follow-up. In theory, the annual review required for the ongoing prescription of COCP could be administrated via such a system. However, whether conducting ‘pill checks’ in this manner is desirable or acceptable to women would require careful consideration.

Alice Tompson, 
Research Officer, University of Oxford. 
E-mail: alice.tompson@phc.ox.ac.uk

Richard McManus, 
NIHR Professor of Primary Care Research, University of Oxford.

Competing interests
Richard McManus has received BP monitoring equipment for research purposes from Omron and Lloyds Pharmacies, and has received honoraria and travel expenses from the Japanese Society of Hypertension and American Society of Nephrology.

REFERENCE

DOI: https://doi.org/10.3399/bjgp17X692777

Long-term benzodiazepine and Z-drugs: are we committing the denominator fallacy?

In a US population of patients co-prescribed benzodiazepines with antidepressants, only 12% went on to long-term use.1 Yet, in this UK study, 35% of all users of BZD are taking these drugs long term.2 How can we reconcile these two findings? One possibility is that UK prescribing is more liberal than in the US. Another is that the UK study looked at BZDs (benzodiazepines and Z drugs), whereas the US study looked at benzodiazepines alone.

Another explanation is the difference between individual risk and prevalence. In a survey of 1 year’s BZD prescriptions, you are likely to include those patients who started in previous years and are still receiving a BZD prescription, but omit shorter-term users from previous years. This increases your numerator (longer-term users) but omits short-term users from the denominator [all users], inflating the percentage of longer-term users. In fact, it is not clear how they calculate ‘that 35% of all users of BZD are taking these drugs long term’. If, for example, the search strategy was ‘all patients prescribed BZD in 2014 or 2015’, then longer-term users who started in 2013 or earlier would be captured, but shorter-term users would not. It may therefore be valid to say that ‘over the time period studied, 35% of patients prescribed a BZD are taking these drugs long term’. This does not, however, equate to the risk to an individual of their BZD use becoming long term (which Bushnell et al estimate at 12%, albeit in a different population).1

We are in danger of committing the prosecutor’s fallacy, assuming P(A|B) = P(B|A); that is, probability of A given B = probability of B given A. The ‘denominator fallacy’,2 failing to identify the denominator correctly, which has been previously described in medicine and beyond, is also relevant here. I would suggest that patients are more interested in individual risks than in population statistics. Doctors of course need to be aware of prevalence, not least when designing services. But with a patient in front of us, it’s important we don’t confuse the two.

Patrick J McNally, 
GP Registrar, St Peter’s Medical Centre. 
E-mail: pj.mcnally@nhs.net

REFERENCES

DOI: https://doi.org/10.3399/bjgp17X692777